C-XZWCAtropos Therapeutics
senescence modulation, phenotypic screening, ATRX
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-XZWC
C-XZWCC-XZWCsenescence modulation, phenotypic screening, ATRX
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Atropos Therapeutics - 2026 Company Profile, Team & Funding - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corpo … 18 Location San Carlos, United States Stage Funding Raised Latest Funding Round Grant (prize money), Jan 01, 2019 , $***** Investors Incite & 1 more Employee Count 3 as on Apr 30, 2026 View Atropos Therapeutics' full profile Sign up to download Atropos Therapeutics' company profile Sign Up for Free Atropos Therapeutics's funding and investors Atropos Therapeutics has raised funding over 3 round s . Its first funding round was on Aug 01, 2018 . Its latest fu … . Its first funding round was on Aug 01, 2018 . Its latest funding round was a Grant (prize money) round on Jan 01, 2019 for $ ***** . 1 investor participated in its latest round. Atropos Therapeutics has 2 institutional investor s . Here is the list of recent funding rounds of Atropos Therapeutics : Date of Funding Funding Amount Round Name Post-Money Valuation Revenue Multiple Lead Investors Other Investors Jan 01, 2019 6975513 Grant (prize money) 6238442 4699306 5958023 8 … 975513 Grant (prize money) 6238442 4699306 5958023 8011747 Sep 30, 2018 9007441 Grant (prize money) 7342803 9095645 2831009 HHS Aug 01, 2018 4061297 Grant (prize money) 3441771 5004518 5411682 HHS Access funding benchmarks and valuations. Sign up today! View details of Atropos Therapeutics 's funding rounds and investors Atropos Therapeutics' founders and board of directors Founder? Claim Profile The founders of Atropos Therapeutics is Tommy Nguyen . Here are the de … ss 3 funding rounds to date. The company's 1st funding round was a $ ***** Grant (prize money) round , raised on Aug 01, 2018 . What does Atropos Therapeutics do? Atropos Therapeutics is involved in developing the drug for aging and cancer treatment. They had developed their proprietary senescence technology FATES discovery platform (short f
%PDF-1.7 %���� 160 0 obj > stream H���yTSw�oɞ����c [���5la� QIBH�ADED���2�mtFOE�.�c��}���0��8��8G�Ng��� ��9�w���߽����'����0 �֠�J��b� 2y�.-;!���K�Z� ���^�i�"L��0���-�� @8(��r�;q��7�L��y��&�Q��q�4�j���|�9�� �V��)g�B�0�i�W��8#�8wթ��8_�٥ʨQ����Q�j@�&�A)/��g�>'K���t�;\�� ӥ$պF�ZUn��� �(4T�%)뫔�0C&�����Z��i���8��bx��E���B �;�����P���ӓ̹�A� om?�W= �x������-�����[���0� ���}��y)7ta�����>j���T�7���@���tܛ�`q�2��ʀ��&���6�Z�L�Ą? �_ ��yxg)˔z���çL�U���*�u�Sk�Se�O4?�c����.�� ��R� ߁��-��2�5������ ��S�>ӣV����d�`r��n~��Y�&�+`��;�A4�� ���A9�=�-� t
Fedora Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Fedora Pharmaceuticals, Inc. Private Company | 2012 | United States | www.fedorapharma.com Private Company | 2012 | United States | www.fedorapharma.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Infectious Diseases Small molecule drug Disease domain score A glimpse into the focused therapeutic areas No Data Technology Platform Most used te … ope And Radiation Chinese Academy of Science Chinese Future Industry Investment Fund Chongqing PSK-Health Sci-tech Development Cincinnati Children's Hospital Medical Center City of Hope CJ CheilJedang ClearPath Cloaked Therapeutics Co-Diagnostics Cohen Veterans Bioscience Cold Spring Harbor Colibri Heart Valve Collagen Solutions Plc Columbus Venture Partners Concentrics Research Consortium AI Corestone Biosciences Cornerstone Animal Health Corning Covenant Animal Health Partn … dministration (FDA) to discuss the steps required for resubmitting the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of simple urinary tract infections (uUTI). The FDA published a Complete Response Letter (CRL) to the company in July, asking for further evidence to support the approval of oral sulopenem for the treatment of adult women with uUTI. In Jan 2020, Wockhardt became the first Indian pharmaceutical company to receiv … n with Cambridge, Mass.-based Foundation Medicine, Inc. In that deal Roche will fund Foundation ’s research and development for more than $150 million for a minimum of five years. That deal totals about $1.03 billion and gives Roche a 56.3 percent stake in Foundation . “This acquisition highlights Roche ’s commitment to developing medicines for spinal muscular atrophy, a serious disease with no effective treatment,” said CMO and Head of Roche Global Product Development Sandra … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Axis Therapeutics Ltd. (Axis Therapeutics Ltd.) - 药物管线_专利_临床试验_投融营收_最新药物:TCRT-ES0-A2 产品 数据 资源 版本对比 预约演示 免费注册 更新于：2025-05-07 Axis Therapeutics Ltd. 子公司 | 2018 | 中国香港 子公司 | 2018 | 中国香港 更新于：2025-05-07 概览 管线布局 药物交易 转化医学 营收 科研基金(NIH) 投资 融资 概览 标签 肿瘤 TCR-T细胞疗法 疾病领域得分 一眼洞穿机构专注的疾病领域 暂无数据 技术平台 公司药物应用最多的技术 暂无数据 靶点 公司最常开发的靶点 暂无数据 疾病领域 数量 肿瘤 1 排名前五的药物类型 数量 TCR-T细胞疗法 1 关联 1 项与 Axis Therapeutics Ltd. 相关的药物 TCRT-ES0-A2 靶点 - 作用机制 - 在研机构 Axis Therapeutics Ltd. 原研机构 Axis Therapeutics Ltd. 在研适应症 实体瘤 非在研适应症 - 最高研发阶段 早期临床1期 首次获批国家/地区 - 首次获批日期 - 100 项与 Axis Therapeutics Ltd. 相关的临床结果 登录后查看更多信息 0 项与 Axis Therapeutics … ope And Radiation Chinese Academy of Science Chinese Future Industry Investment Fund Chongqing PSK-Health Sci-tech Development Cincinnati Children's Hospital Medical Center City of Hope CJ CheilJedang ClearPath Cloaked Therapeutics Co-Diagnostics Cohen Veterans Bioscience Cold Spring Harbor Colibri Heart Valve Collagen Solutions Plc Columbus Venture Partners Concentrics Research Consortium AI Corestone Biosciences Cornerstone Animal Health Corning Covenant Animal Health Partn … ted before on the development of KX-02 for glioblastoma multiforme in China. To fund the new Axis, Athenex will provide the company with $30 million in cash. Additionally, Athenex will provide $55 million of Athenex common stock to Xiangxue Life Sciences as an upfront payment. Axis Therapeutics will also pay various clinical and regulatory milestones of up to $110 million to Xiangxue Life Sciences. Xiangxue Life Sciences will retain the mainland China rights to the technology
Avvinity Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 31 May 2026 Avvinity Therapeutics Ltd. Holding Company | 2016 | West Virginia, United States | www.avvinity.com Holding Company | 2016 | West Virginia, United States | www.avvinity.com Last update 31 May 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Avvinity Therapeutics Ltd. Login to view more data 0 Patents (Medical) associated with A … ope And Radiation Chinese Academy of Science Chinese Future Industry Investment Fund Chongqing PSK-Health Sci-tech Development Cincinnati Children's Hospital Medical Center City of Hope CJ CheilJedang ClearPath Cloaked Therapeutics Co-Diagnostics Cohen Veterans Bioscience Cold Spring Harbor Colibri Heart Valve Collagen Solutions Plc Columbus Venture Partners Concentrics Research Consortium AI Corestone Biosciences Cornerstone Animal Health Corning Covenant Animal Health Partn … y , Horizon’s chief executive officer said in a statement. Horizon said it will fund Avvinity with about $7.5 million in startup capital, while Centauri will license its Alphamer technology to Avvinity for an initial three year period. Horizon said it has already donated $3.5 million to Avvinity and will commit the remaining amount pending the progression of three developmental programs, Horizon said. What those initial programs will initially target though, was not publicize … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Dermatology Collaboration and Licensing Agreements Benchmark Report 2026: Structured Analysis of 500+ Deals and How Partnerships are Designed, Negotiated, and Executed Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets close in 27m UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets close in 27m FTSE 100 10,550.41 +88.78 +0.85% GBP/USD 1.3208 +0.0044 +0.33% GBP/EUR 1.1601 +0.0011 +0.09% FTSE 250 23,241.06 +139.54 +0.60% AIM 772.55 -4.82 -0.62% GOLD FUTURES 4,031.20 +22.40 +0
Faes Farma - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 12 Jun 2025 Faes Farma Public Company | 1933 | Spain | 1,000-5,000 | BME: FAE | faesfarma.com Public Company | 1933 | Spain | 1,000-5,000 | BME: FAE | faesfarma.com Last update 12 Jun 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Faes Farma Login to view more data 0 Patents (Medical) associated with Faes Farma Login to view more data 1 Literatures (Med … s shareholders (founding families and 21 Invest SGR S.p.A. on behalf of managed fund 21 Investimenti III ("21 Invest")). Hogan Lovells Studio Legale ("Hogan Lovells") is acting as legal advisor. J.P. Morgan SE ("JPM") is acting as Faes Farma's exclusive financial advisor and debt financing provider in connection with the transaction. Cuatrecasas Legal SLP ("Cuatrecasas") and Chiomenti Studio Legale ("Chiomenti") serve as legal advisor and Ernst & Young Servicios Corporativos … ope And Radiation Chinese Academy of Science Chinese Future Industry Investment Fund Chongqing PSK-Health Sci-tech Development Cincinnati Children's Hospital Medical Center City of Hope CJ CheilJedang ClearPath Cloaked Therapeutics Co-Diagnostics Cohen Veterans Bioscience Cold Spring Harbor Colibri Heart Valve Collagen Solutions Plc Columbus Venture Partners Concentrics Research Consortium AI Corestone Biosciences Cornerstone Animal Health Corning Covenant Animal Health Partn … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Avvinity Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 31 May 2026 Avvinity Therapeutics Ltd. Holding Company | 2016 | West Virginia, United States | www.avvinity.com Holding Company | 2016 | West Virginia, United States | www.avvinity.com Last update 31 May 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Avvinity Therapeutics Ltd. Login to view more data 0 Patents (Medical) associated with A … ope And Radiation Chinese Academy of Science Chinese Future Industry Investment Fund Chongqing PSK-Health Sci-tech Development Cincinnati Children's Hospital Medical Center City of Hope CJ CheilJedang ClearPath Cloaked Therapeutics Co-Diagnostics Cohen Veterans Bioscience Cold Spring Harbor Colibri Heart Valve Collagen Solutions Plc Columbus Venture Partners Concentrics Research Consortium AI Corestone Biosciences Cornerstone Animal Health Corning Covenant Animal Health Partn … y , Horizon’s chief executive officer said in a statement. Horizon said it will fund Avvinity with about $7.5 million in startup capital, while Centauri will license its Alphamer technology to Avvinity for an initial three year period. Horizon said it has already donated $3.5 million to Avvinity and will commit the remaining amount pending the progression of three developmental programs, Horizon said. What those initial programs will initially target though, was not publicize … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
%PDF-1.7 %���� 2942 0 obj >] /Length 1236 >> stream x����mg! ^^n!>a!Qi Yi i3uM Kg{K;[���pw�D_[��ʨ��ܢ�"��ڶ��ִ�� {��嫏�>�������@�bd`f���������� �/F�r�AVEC6!�@��Ba%�F�� 7 �T6� �Tt�KL���G���>#�cMd� �1��n1�03#�Y���aޯo�램�32:'0�4��R4�)[6��k�y��}�s33��/�~����?C�ڪK[K���W����}ڏ�{���=�ٓ��:�]� ��/m5���)x�����uZ X�=�����fٴ���� r�V���#.ߴ� �䯖�Ƕ �� ��=� kT)�z���՞.�r.%��=��۲�{fd��Ƨ�^�wLs��O�� )����4�����g�3����e�r���%��ތ�7������K�^�%V4}߽���T�v� �]Z8Ue^�G E�����C�3Lț��q�יU�A�� > stream x��|y`TE�wUݽ��k�N����ݡ�/$$�,@ !H! քMv1�* (�踌����PL1�}���d ��qF�� � ����#����=�K?E … �b�l�λ��~�*Z��.H@$�0 �Z��J����K���s ���_�C9��-_0��zޓf�����u'���{� �zZK��rfP(=l�M��w�J��;9���%mk]et�j�ؖ�Eb�r��r��>��vs��R/K�sW��1��+萶�A�PBr�Չ�W`G݈����>G��� O}��P��嵋��\��H��U�s�*���]��� _c��{��q/W�-1X� LY����TZ�f �r��C�y�=�VH~��'j��p�+(�r��)B�>�ÿ^���")_�m�� �D��s�0���{��^z%���ڵr��f^��?��� S8LE�� �·[��Ks�p4=�]}��A�ʺ_N�:����>�c��� ��#��������MQs����d*�0ז�:^���"_�cF g�W��o]G YE&a7 �M�A�~��?���:lr���� �1^;�tK0���s�i�L�����Jw��GW!�x� … am endobj 12097 0 obj >] /Length 92119 >> stream x���T[�( 79 � ���HF2HX��ArA@rFP@XA@2J��U�ET�䜑(YrX�����s�y����7ƻ {��s�J��fU���� �4p�$�t� �e��TW(�x�hi�np���I���QҲ5TR{�!#k�k������SA? ��[����+% ����������� P�~�y��� `S`�P`����ú���aa������ j/�X88ظ8xx��`k��R�Q^�ǿ����ՃJ(8!���ve+���/va+�"�4�t��9nprq����KHsWAQIYEUWO�������桭�����#o��O|�B���?���JLz�����uZ^~Aᛢ�Ҫ�ں� �_�~kk���� �����������s}co�������� ��������6...�/,�ǘ�x��)� x\a &����[�J
Aruvant Sciences, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 05 Mar 2026 Aruvant Sciences, Inc. Startups | Subsidiary Company | 2018 | New Jersey, United States | 10-50 | aruvant.com Startups | Subsidiary Company | 2018 | New Jersey, United States | 10-50 | aruvant.com Last update 05 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Congenital Disorders Endocrinology and Metabolic Disease AAV based gene therapy Disease domai … ope And Radiation Chinese Academy of Science Chinese Future Industry Investment Fund Chongqing PSK-Health Sci-tech Development Cincinnati Children's Hospital Medical Center City of Hope CJ CheilJedang ClearPath Cloaked Therapeutics Co-Diagnostics Cohen Veterans Bioscience Cold Spring Harbor Colibri Heart Valve Collagen Solutions Plc Columbus Venture Partners Concentrics Research Consortium AI Corestone Biosciences Cornerstone Animal Health Corning Covenant Animal Health Partn … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Pauline Jen Ryan - Advisor at Red Sky Partners | The Org Platform Enrich Pricing Log in Sign up Red Sky Partners Pauline Jen Ryan Unverified Pauline Jen Ryan Advisor Contact Pauline Jen Ryan is a business advisor and consultant with over 20 years of experience in the pharmaceutical and biotech industries. Pauline has held senior positions at Atropos Therapeutics Inc., Proteostasis Therapeutics, Inc., and ImmunoGen, Inc., where they oversaw corporate development and operations. Ryan has also served on the board of directors for Lumio and Verik Bio, and was the CEO of Solmap Pharmaceuticals, I
Pauline Jen Ryan | Red Sky Partners Red Sky Partners Growth and Value Creation Strategy Home Our Team Tim Surgenor Philip Gotwals, Ph.D. Richard Douglas, Ph.D. Jessica Duda Pamela Hay Mason “Skip” Irving, III Chris Kiritsy Doris Peterkin Pauline Jen Ryan Nabil Uddin Our Clients Contact Us Pauline Jen Ryan Advisor Pauline Jen Ryan Pauline Jen Ryan Pauline Jen Ryan joined Red Sky Partners in 2014 and serves clients by taking on interim C-level roles (CEO, CBO, COO) or acting as an advisor on general corporate and business development matters. Her particular expertise is with small- to mid-size b … ute and is on the National Board of Directors for the Distinguished Young Women scholarship program. She was previously a member of the Board of Directors for Lumio and ReviveMed, startups incubated at the Martin Trust Center for Entrepreneurship at MIT, and also for Solmap Pharmaceuticals (acquired by Forma Therapeutics). Pauline was also a founding member of the Biotechnology Industry Organization’s Business Development Advisory Committee and launched the BIO Business Devel
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Search - ModernAesthetics YoungMD Connect Subscribe Log In Create Account Back Face Value MATV News Meet the Board Revision Skincare Updates in Energy-Based Devices RF Microneedling Safety Session Highlights YMDC Member articles Energy-based Devices Injectables Minimally Invasive Practice Development Regenerative Medicine Skincare Surgical Weight Loss Sponsored Articles Energy-based Devices Injectables Minimally Invasive Practice Development Regenerative Medicine Surgical Skincare The Aesthetic Society The Aesthetic Society ASDS Annual Meeting Octane ATF 2026 Music City SCALE Octane ATF … oxina/2473204/ Revance Therapeutics, Inc. has resubmitted its Biologics License Application (BLA) to FDA for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The submission is in response to the Complete Response Letter (CRL) issued by FDA in October 2021. The Dr. J. Kevin Duplechain Named New President of AACS https://modernaesthetics.com/news/dr-j-kevin-duplechain-named-new-president-of-aacs/2473198/ Dr. J. Kevin Duplechain is the n
%PDF-1.5 %���� 108 0 obj > endobj xref 108 130 0000000016 00000 n 0000003775 00000 n 0000003889 00000 n 0000005662 00000 n 0000006089 00000 n 0000006815 00000 n 0000007229 00000 n 0000007657 00000 n 0000007912 00000 n 0000007949 00000 n 0000007997 00000 n 0000008623 00000 n 0000008737 00000 n 0000008849 00000 n 0000008965 00000 n 0000015836 00000 n 0000023508 00000 n 0000028152 00000 n 0000036434 00000 n 0000043599 00000 n 0000050992 00000 n 0000051129 00000 n 0000051378 00000 n 0000052104 00000 n 0000059774 00000 n 0000060168 00000 n 0000060620 00000 n 0000061035 00000 n 0000061432 00000 n 00 … +bv�@~?Y:z|!�q��^i|F�.�{���G/��>�+����� endstream endobj 211 0 obj >stream application/pdf LT logo 2020 master 2020-05-18T11:26:28-04:00 2020-05-18T11:26:28-04:00 2020-05-18T11:26:28-04:00 Adobe Illustrator CC 23.0 (Macintosh) uuid:41824008-ffa2-474c-b06f-1e5ed562368f xmp.did:cd8525eb-ef06-4d7e-925f-2a8517ddff79 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:ee98360e-b033-43b1-a8e8-86cc3d028b51 xmp.did:ee98360e-b033-43b1-a8e8-86cc3d028b51 uuid:5D20892493BFDB1191 … .000000 0.003100 0.003100 endstream endobj 212 0 obj > endobj 213 0 obj >stream application/pdf Senolytic Cover image 2021-07-05T12:35:47-04:00 2021-07-05T12:35:47-04:00 2021-07-05T12:35:46-04:00 Adobe Illustrator 24.2 (Macintosh) uuid:a3e741e9-78ef-194d-8b76-56f18a1114ac xmp.did:a5593856-08bf-4e8b-9f8d-59b9706a79c3 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:b7009963-1197-4df9-bc74-e6e199ccc10b xmp.did:b7009963-1197-4df9-bc74-e6e199ccc10b uuid:5D20892493BFDB11914 … 37284d2c712 xmp.did:304fe2d7-4712-4ac2-a629-fe9a2655b410 default converted from application/x-indesign to application/pdf Adobe InDesign 15.1 (Macintosh) / 2021-07-07T09:56:46-04:00 application/pdf Adobe PDF Library 15.0 False endstream endobj 216 0 obj > endobj 217 0 obj >stream H�\Vy4�{ ��G� E�J�B��R��&[j�dI��4mOӛJ�M�0E�r,�aZ�-Ո�6�xiy��!�O���ƙ�N�̙>��>����wg�y���5-V jh�}��hYBSec!w:��O۾N� ��Ѣ�>Cs��w���R�N� ��gΐo A�NI��b��� �����_{��F��ˡ�}�-�/Q� HKۤJRs)�h�t';�1�@�m�1 … K,�g��"�$��*�� �u�7�.�J����%}�E�fP#�W��p-�A"&;6�\���d�(@_p��M >stream application/pdf LT logo 2020 master 2020-05-18T11:26:28-04:00 2020-05-18T11:26:28-04:00 2020-05-18T11:26:28-04:00 Adobe Illustrator CC 23.0 (Macintosh) uuid:41824008-ffa2-474c-b06f-1e5ed562368f xmp.did:cd8525eb-ef06-4d7e-925f-2a8517ddff79 uuid:5D20892493BFDB11914A8590
#4 - Andy Koff - Preventing Quiescent Cells from Turning Senescent - A Unique Approach to Fighting Senescent Cells by Atropos Therapeutics - The Simple BioTech Podcast | Podcast on Spotify
Estée Lauder Companies and Atropos Therapeutics Partner to Discover Botanical Senomodulators - - PracticalDermatology Subscribe Log In Create Account Back Acne & Rosacea Aesthetics & Cosmeceuticals Atopic Dermatitis General Topics Hair & Nails Infections & Infectious Disease Other Dermatitis Pigmentary Disorders Pediatric Practice Management Psoriasis Psoriatic Arthritis Rare Disease Skin Cancer & Photoprotection Skin of Color Sponsored Content View All VIDEOS Type II Inflammation Journal Club IL-17 Journal Club Skin Minute The Practical Dermatology Roundtable: Adjuvant Skin Cleansing and Mois
Lauder partners with biotech firm on botanical senomodulators research Home Categories Ingredients Packaging Regulatory Manufacturing Company news Body Care Colour Cosmetics Fragrance Hair Care Skin Care Male Grooming Digital Marketing Retail Distribution Recruitment Pure Beauty Job board Events Directory Search Close search Subscribe Login Password Password Remember me Forgot password? Close login form Cosmetics Business Ingredients Lauder partners with biotech firm on botanical senomodulators research Lauder partners with biotech firm on botanical senomodulators research By Julia Wray | Publ
| BeautyMatter Skip to Content Business Categories Reports Podcasts Events Awards Webinars Contact Memberships Login Business Categories Reports Podcasts Events Awards Webinars Contact My Account About THE ESTÉE LAUDER COMPANIES PARTNERS WITH ATROPOS THERAPEUTICS Published September 18, 2020 Kelly Kovack Published September 18, 2020 Photo: Landon Arnold via Unsplash The Estée Lauder Companies signed a joint development agreement with biotech firm Atropos Therapeutics. WHO: Founded in 2018, Atropos is a biotech platform company focused on the discovery, development, and commercialization of the
Atomwise inks four new deals for AI-based drug discovery Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media
--> Verifying that you are a human... Please refresh the page to continue (if it does not automatically refresh). If you still see this page even after refreshing, try enabling JavaScript and/or cookies in your browser.
--> Atropos Therapeutics top of page Home Team Science & Pipeline News Work with us More Use tab to navigate through the menu items. HARNESSING SENESCENCE FOR HUMAN HEALTHSPAN Atropos aims to treat aging-related diseases and cancer and improve healthspan with approved novel senescence- targeting drugs. NEWS July 26, 2021 Atropos is highlighted in Longevity Technology’s Senotherapeutics Report. Read more >> Atropos, the Fate whose duty it was to cut the threads of life. Robert S. Holzman, MD The Legacy of Atropos, the Fate Who Cut the Thread of Life
The Estée Lauder Companies and Atropos Therapeutics Announce a Joint Collaboration Agreement to Discover Senomodulators - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business The Estée Lauder Companies and Atropos Therapeutics Announce a Joint Collaboration Agreement to Discover Senomodulators August 13, 2020 | 1 min read Twitter LinkedIn Facebook Email Print In a quest to explore the botanical space for molecules that modulate senescence, Atropos Therapeutics Inc … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newslett … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=false -dDownsampleGrayImages=false -dDownsampleColorImages=false -dAutoFilterColorImages=false %%+ -dAutoFilterGrayImages=false -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=false -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH -sOutputFile=? ? 5 0 obj > stream x��YɎ]��߯��H��9�Dq�cK��0ڒ��[�-'F�>� ^��@Ћ�u �d�U|?�ָ����� T��m4���2_��E�7�3 … �� =N$�\>Χ���`B&O?�^;c�5] �J 5�.��� ��Қޟ���n�9D1MN���R6Լ7�J?u�k����W�>�m�wn��rfp�i"�*b ���la� k%3�A��D�� ��e���nQ^t]���).�ݒ�T��g[QS�ynЩ ���o��}�\y9"�wJ}��q�n��:l~I�����09\d��h�ό�w�{��@x�pȟf{U��g|3���2� u����_�[2�0ټ6u���5��?�� �������m��+�'�͚@l�;��ޮ� a�o���6�� �%�S~t~��F�>���$�U� 5[���'�|��|�I�����@G��^;���Y:~TN|c.a����Ѵ��ڛspZ&��0N1����Rݨ� ��I�b%��3� �����C���;/��IFl�8�_���s$�� aaY�AS '��0y�+��`�u�y���� �B��a�Uh#��WFF�e CA�&=�`a���J7��_�n�f*J̐�����U*�Q+
PK!���ϒ�[Content_Types].xml �(�̕MO1��&��M��-`b�a���QI��k�lC����݂Ę$K��mv�y�g���`�2:[B@�l�zy�e`K'���e�йf��Rhg�`k@6�� &k��h���� �XV`��3S���f܋r.f����/�%�ԡZ� w0 M��*~ސ�Ȳ���ګ`�{�JA��/�����:�12��Jy���7:�3?l�bj����E�Ga"_i����y�_���M���ʅ���+2:Ocn����{��b�i����$|$G��p\��� ��⢄.%��uGVł=�\i8X�rZ�J�%\�� ��P�4��H;s�>����67M�i�zoɥ#+��DΐY���B��5�V��$��~����"c 'Z����k�RRF%������8���EsܙF|�0�2�Xn/ɢ�1�=c�W�7����PK!�[*���xl/workbook.xml�V]o�8}_i�C&�4O!qHB�JG� Ҵ[ ��X�������BU���@(L��A`�_���{� �_�Ui i~����� �K� `rdJՑmˬ �=^++.*�`(ֶ���,QU
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Search - PracticalDermatology Subscribe Log In Create Account Back Acne & Rosacea Aesthetics & Cosmeceuticals Atopic Dermatitis General Topics Hair & Nails Infections & Infectious Disease Other Dermatitis Pigmentary Disorders Pediatric Practice Management Psoriasis Psoriatic Arthritis Rare Disease Skin Cancer & Photoprotection Skin of Color Sponsored Content View All VIDEOS Type II Inflammation Journal Club IL-17 Journal Club Skin Minute The Practical Dermatology Roundtable: Adjuvant Skin Cleansing and Moisturizing View All PODCASTS The Practical Dermatology Podcast The Science of Skin Podcast … open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions to help make life better for people living with atopic dermatitis. The challenge, "Transforming Atopic Der First Patient Enrolled in AVITA Therapeutic’s Pivotal Study of RECELL System for Vitiligo https://practicaldermatology.com/news/first-patient-enrolled-in-avita-therapeutics-pivotal-study-of-recell-system-for-vitiligo/2460528/ AVITA Therapeutics,
Atomwise and Atropos Launch Joint Venture to Discover Senescence Modulating Small Molecules for Cancer Patients – 1stOncology™: Cancer Intelligence Service 1stOncology™: Cancer Intelligence Service 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Skip to content 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers , signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology! Access Free Conference … Abraham Heifets, Ph.D. CEO and Co-Founder of Atomwise. "We are excited to apply our technology to targets that are considered to be intractable and advance the discovery and development of drugs that modulate cellular senescence to treat cancer." Under the terms of the agreement, the joint venture company will have access to Atropos’ and Atomwise’s cutting-edge technology and expertise in aging, cancer biology, computational and medicinal chemistry, and
--> Science & Pipeline | Atropos Therapeutics top of page Home Team Science & Pipeline News Work with us More Use tab to navigate through the menu items. SCIENCE & PIPELINE Atropos is a drug discovery platform to identify chemical matter that can modulate the formation of senescent cells, both for aging applications (senosuppressors) and oncology applications (senostimulators). What are senescent cells? Senescence is classically thought of as a cellular state induced by various stressors in which cells irreversibly exit the proliferative cycle and elaborate a program of gene expr
How a Combination Therapy Developed at MSK Benefits People With a Rare Gastrointestinal Cancer | Memorial Sloan Kettering Cancer Center Skip to main content Skip to footer For appointments, call: 800-525-2225 Memorial Sloan Kettering Cancer Center Sloan Kettering Institute Research Changing how the world understands and treats cancer Our scientists pursue every aspect of cancer research—from exploring the biology of genes and cells, to developing immune-based treatments, uncovering the causes of metastasis, and more. Programs & Centers Sloan Kettering Institute Pursuing basic and translati … (R01FD005731 and R01FD005105), Cycle for Survival, the Geoffrey Beene Research Fund, the Shuman Fund, the GIST Cancer Research Fund, the GIST Cancer Awareness Fund, and Grail. Dr. Chi has relationships with or financial interests in ORIC Pharmaceuticals, Deciphera, Exelixis, Merck, and Pfizer. Dr. Tap has relationships with or financial interests in AcademicCME ; Atropos Therapeutics, Inc.; Axis Medical Education; C4 Therapeutics; Certis Oncology Solutions; Daiichi Sankyo; D
A NEW BIOTECH PODCAST IS LIVE ON @simplebiotech 🎙 🧬👩🏻🔬👨🏻🔬🧫🧪 https://simplebiotechpodcast.com/andy-koff-preventing-quiescent-cells-from-turning-senescent/ Simple Biotech Podcast #4 - with Dr. Andrew Koff who is a molecular biologist at Memorial Sloan Kettering cancer center. He studies the biochemical, genetic, and cellular mechanisms that control how cells replicate and how they decide to continue replicating or stop. This research has many applications in oncology and aging research. He is also the founder and President of Atropos Therapeutics, a company working to use resear
Atropos Therapeutics – Senostimulators/Senosuppressors Donate Login About Mission Board of Directors Scientific Advisory Board Team Annual Reports Contact Research Supported Projects Investments Publications Education Summer Scholars Post-Baccalaureate Host Lab Signup News Outlet Investor Network About Join Reports Advocacy Video Initiatives Engaging the Press Crowdfunding Sponsored Projects Advocacy Topics A4LI Resources Rejuvenation Roadmap Infographics Longevity Topics Find Longevity Events EARD Conference Archive Get Involved Donate Be a Lifespan Hero Hall of Heroes Join the Lifespan
--> Team | Atropos Therapeutics top of page Home Team Science & Pipeline News Work with us More Use tab to navigate through the menu items. TEAM Andrew Koff, PhD Founder and Director William D. Tap, MD Co-founder and Director Pauline Jen Ryan CEO and Director Dan Garza, PhD VP, Drug Discovery Biology Nathanie Trisnadi, PhD Director of Lab Operations & Research Scientist ADVISORS ERKAN BALOGLU, PH.D., MBA Medicinal chemist with 20+ years experience in small molecule drug discovery and development at GSK and multiple small biotech companies, 5 INDs and 1 NDA submissions, inventor on 30+
Atropos Therapeutics News and Press Releases | PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Ove … ated to make your job easier. In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need. LEARN MORE « 1 --> 1 » Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected. Items per page: 25 per page 50 per page 75 per page 100 per page Contact PR Newswire Call PR Newswire at 888-776-0942 from 8 AM - 9 PM ET Chat with an Expert Contact Us … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Atomwise and Atropos Launch Joint Venture to Discover Senescence Modulating Small Molecules for Cancer Patients - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tren … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Atomwise and Atropos Launch Joint Venture to Discover Senescence Modulating Small Molecules for Cancer Patients September 11, 2019 | 2 min read Twitter LinkedIn Facebook Email Print Atomwise Inc., a leader in artificial intelligence (AI) for drug discovery, and Atropos Therapeutics, Inc., a s … said Abraham Heifets, Ph.D., CEO and Co-Founder of Atomwise. “We are excited to apply our technology to targets that are considered to be intractable and advance the discovery and development of drugs that modulate cellular senescence to treat cancer.” Under the terms of the agreement, the joint venture company will have access to Atropos’ and Atomwise’s cutting-edge technology and expertise in aging, cancer biology, computational and medicinal chemistry, and artificial intel … r $50 million from leading venture capital firms to support the development and application of its AI technology. Learn more at www.Atomwise.com or follow @AtomwiseInc. View source version on businesswire.com: https://www.businesswire.com/news/home/20190911005185/en/ Contacts Atropos Therapeutics Ethan Than [email protected] Atomwise Sara Dunn [email protected] Source: Atomwise View this news release online at: http://www.businesswire.com/news/home/201909110051 … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
The Estée Lauder Companies and Atropos Therapeutics Announce a Joint Collaboration Agreement to Discover Senomodulators Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Galler … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
--> Work with us | Atropos Therapeutics top of page Home Team Science & Pipeline News Work with us More Use tab to navigate through the menu items. WORK WITH US PARTNERS We are looking for new partners, investors, and colleagues to support our initiative. Please contact us in one of the ways below. CONTACT US Mailing: PO Box 412, Belmont, California 94002 Laboratory: MBC BioLabs, 733 Industrial Road, San Carlos, CA 94070 [email protected] Team Science & Pipeline News Work with us ©2018 by Atropos Therapeutics Inc.. Proudly created with Wix.com bottom of p
Taiwan - Biotech Companies - Careers Page About Directory Promoted Listings Purchase Data Drug Pipelines Data Licensing Weekly Update Newsletter Contact Taiwan - Biotech Companies - Career Pages Stem Cell Therapeutics , Changed name to Trillium Therapeutics, Jun 2014 Auro Vaccines Pearl River, NY Vaccines Mercury Pharmaceuticals , Website gone, strange urls, not sure what's going on Famar Avlonas, Greece Contract Manufacturing - Small Molecules Tribune Therapeutics Stockholm, Sweden Therapies targeting CCN protein Co-D Therapeutics , Professor-run, 10 years, … Saliva-based Diagnostics 3PrimeDx , No website Nov 2018 - Mar 2020; SBIR grant The Reg Consultants , Website down May 2023 - Dec 2023 One Biosciences Paris, France Therapeutic target discovery using AI & Single Cell technologies Boston Strategic Corporation , Changed name to Strategia Therapeutics, Apr 2015 Cimeio Therapeutics Basel, Switzerland Hematopoietic stem cell transplantation and adoptive cell therapies Lumenblation Medical , Rena … part of MW LifeSciences Corinth MedTech , Website down Sep 2023; Did not submit annual report in 2022 or 2023 Bayer Mailand , Italy Small Molecules New York, NY Mispro is a contract vivarium organization (CVO) offering a network of full-service vivarium rental facilities for preclinical rodent studies. AgeneBio Baltimore, MD Neurological & psychiatric diseases Auris Health , Acquired by J&J, Apr 2019, $3.4B; fka Auris Surgical Robots Brai … p;P10 BIOSCIENCES , Believed defunct, Never registered as MA business, had SBIR grant Sensidose , Acquired by Navamedic, Mar 2023 , Website down Sep 2025 - Dec 2025 Signature Therapeutics , Merged into Ensysce Biosciences, Dec 2015 Augurex Life Sciences Vancouver, BC Biomarker discovery & validation Accellacare Winston-Salem, NC Clinical Research Inquis Medical Menlo Park, CA Venous thromboembolism treatment Delpharm Saint-Remy, Fran … n Therapeutics 2012 CERAMIDE THERAPEUTICS , No info. Jun 2015. $1.5M SBIR grant 2011 TriMetis Life Sciences Germantown, TN Biospecimens Perseo Pharma Muttenz, Switzerland Therapeutic Enzymes Delivery Promaxo Oakland, CA Small form MRI Bluefish Pharmaceuticals Stockholm, Sweden Generics pharmaceutical company Tw
Avalon GloboCare Corp. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 09 Dec 2025 Avalon GloboCare Corp. Public Company | 2014 | New Jersey, United States | < 10 | NASDAQ: ALBT | www.avalon-globocare.com Public Company | 2014 | New Jersey, United States | < 10 | NASDAQ: ALBT | www.avalon-globocare.com Last update 09 Dec 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Hemic and Lymphatic Diseases Immune System Diseases AAV based gene t … gent-free equivalents of membrane proteins can be designed. Here, we report the application of the QTY code on six variants of cytokine receptors, including interleukin receptors IL4Rα and IL10Rα, chemokine receptors CCR9 and CXCR2, as well as interferon receptors IFNγR1 and IFNλR1. QTY-variant cytokine receptors exhibit physiological properties similar to those of native receptors without the presence of hydrophobic segments. The receptors were fused to the Fc region of immu … ope And Radiation Chinese Academy of Science Chinese Future Industry Investment Fund Chongqing PSK-Health Sci-tech Development Cincinnati Children's Hospital Medical Center City of Hope CJ CheilJedang ClearPath Cloaked Therapeutics Co-Diagnostics Cohen Veterans Bioscience Cold Spring Harbor Colibri Heart Valve Collagen Solutions Plc Columbus Venture Partners Concentrics Research Consortium AI Corestone Biosciences Cornerstone Animal Health Corning Covenant Animal Health Partn … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Eyconis Advancing life-changing treatments for eye disease Transforming long-acting, effective delivery of clinically validated and emerging medicines for ophthalmology. Eyconis is developing novel therapies to transform the lives of patients with eye disease. There is a high unmet need for improved ophthalmology therapeutics particularly in wet age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) and geographic atrophy (GA). We have the potential to be the first to achieve long-acting and effective delivery of multiple clinically validated and eme … ). He earned his PharmD from the University of Illinois at Chicago, completed a fellowship in health policy and economics at Thomas Jefferson University, and holds MBA degrees from Columbia University and the University of California, Berkeley. LINKEDIN Emmett T. Cunningham, Jr, MD, PhD, MPH Co-Founder & Executive Chairman of the Board Emmett T. Cunningham, Jr, MD, PhD, MPH Co-Founder & Executive Chairman of the Board Dr. Emmett Cunningham co-founded Eyconis, Inc., a … ifornia at San Diego for research conducted at The Salk Institute. He completed residency in ophthalmology and fellowship training in Corneal Disease and Uveitis at UCSF and The Francis I. Proctor Foundation, a medical retina and uveitis fellowship at Moorfields Eye Hospital in London, and a fellowship in public health ophthalmology with Prof. Alfred Sommer at the Wilmer Eye Institute in Baltimore. In addition to his professional commitments, Emmett is actively involved in te … ifornia at San Diego for research conducted at The Salk Institute. He completed residency in ophthalmology and fellowship training in Corneal Disease and Uveitis at UCSF and The Francis I. Proctor Foundation, a medical retina and uveitis fellowship at Moorfields Eye Hospital in London, and a fellowship in public health ophthalmology with Prof. Alfred Sommer at the Wilmer Eye Institute in Baltimore. In addition to his professional commitments, Emmett is actively involved in te … hemical Engineering and Biological Sciences from Stanford, while on an athletic scholarship, and earned MD, PhD and MBA degrees from Duke University. LINKEDIN Aaron Royston, MD, MBA Board Observer, Managing Partner, venBio Partners Aaron Royston, MD, MBA Board Observer, Managing Partner, venBio Partners Aaron Royston, MD, MBA is Managing Partner
--> --> Atropos Therapeutics jobs, careers, overview, and news by VentureLoop --> --> --> --> MENU Toggle navigation Home Job Search internships --> blog widget --> Login --> --> Atropos Therapeutics 0 Job Address San Carlos , CA Website atroposthera.com Est. Since 2018 Investors QB3 About --> About Atropos Therapeutics Atropos Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs against aging disorders and cancer using its proprietary senescence technology. Our pipeline is preclinical stage and is NIH-funded. We are a relatively new company and welcome
inhite ventures --> MENU ☰ ✕ Home Carl Jones, 🇺🇸 📃 Articles 📈 Stocks: NASDAQ, NYSE 🏦 Banks 📌 SVVC Family | In Loving Memories Tran Minh Chieu, ESQ. ⚖ 🛢 O&G, 1940s 🛢 O&G, 1980s Nguyen Duy Long, CAPT ⛪️ Church Sponsors   … emic scholarships and achieved athletic awards; he was granted a full U.S. Navy scholarship to an officer candidate school (OCS). He received military training and education at the U.S. Naval War College, https://www.usnwc.edu , in Newport, Rhode Island where he achieved and held outstanding marks across the charts. In the last ten (10) years, Carl has been traveling to several cities and visiting startup communities, spending some time living in the ASEAN region and returnin … ns in 1983 under their American names and of the names of their senior American fellowship church sponsor families . The family now resides in the states of California, Florida, and Texas, and family members have previously lived in New York, Connecticut, Maryland, New Jersey, Virginia, and Washington, D.C. Having proven management experience and leadership skills in both corporate and startup environments, as well as having obtained a security clearance to work on government … lio management from early-stage to exits, M&As and IPOs; venture capital ("VC") fund formation and opportunity funds ranging from $50 to $500 million. Well connected in the “VC/startup” ecosystem and with investors; invitation to join the National Venture Capital Association (NVCA.org), http://www.nvca.org ; traveled locally and globally and can speak additional languages; established relationships and contacts in areas of media, legal, government, stock markets, … tion & Human Relations, Certificate of Recognition and received Human Relations Award and Special 100 Percent Recognition, 2002. Project Management Professional (PMP), Enterprise / Project Management Office (E/PMO), Certificate of Completion, 2001. Software Development Life Cycle (SDLC) / Lean / Agile, Certificate of Completion, 2000. UNDERGRADUA
--> --> jobs, careers, overview, and news by VentureLoop --> --> --> --> MENU Toggle navigation Home Job Search internships --> blog widget --> Login --> Byers Hall Suite 214 1700 4th Street San Francisco, CA 94158-2330 Overview: Portfolio Companies: 4:59 NewCo 4D Molecular Therapeutics 712 North Abalone Bio Abate Med Ablexis AccuraGen Holdings Accurus Biosciences Achelois Pharmaceuticals Acne.org Acrigen Acrobat Genomics Actym Therapeutics Addition Therapeutics Adheren AfaSci Agenovir Agevio Therapeutics Aikium Akoya Biosciences Alpine Roads Alveo Technologies Alzeca Biosciences Amarantus Bio
Aging Companies (for profits) - Google Sheets Die Datei kann in Ihrem Browser nicht geöffnet werden, weil JavaScript nicht aktiviert ist. Aktivieren Sie JavaScript und laden Sie die Seite noch einmal. Diese Browserversion wird nicht mehr unterstützt. Installieren Sie bitte einen unterstützten Browser. Aging Companies (for profits) Tab Extern Freigeben Anmelden Datei Bearbeiten Ansicht Einfügen Format Daten Tools Erweiterungen Hilfe Bedienungshilfen Fehlerbehebung Nicht gespeicherte Änderungen in Drive &n … NA interference (RNAi) therapieus to silence disease-specific genes, with broad application to many age-related disease areas FDA approved Tx proteostasis (h)ATTR(-CM), AD, HD, ALS, T2D, MASH, NAFLD, hypercholesterolemia, hypertension humans 82 ATTR, APP, PCSK9, AGT, HTT, SOD-1, HSD17B13 siRNA pharma Yvonne Greenstreet, Kevin Fitzgerald Boston yes ALNY $39,261 2100 2442 2002 >$100M Onpattro, Amvuttra, Leqvio science presentations 2025-02-02 2024-08-15 *Borderline: Broad pr
Agilis Biotherapeutics LLC - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 29 May 2026 Agilis Biotherapeutics LLC Subsidiary Company | 2013 | Massachusetts, United States | < 10 | www.agilisbio.com Subsidiary Company | 2013 | Massachusetts, United States | < 10 | www.agilisbio.com Last update 29 May 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Agilis Biotherapeutics LLC Login to view more data 0 Patents … ope And Radiation Chinese Academy of Science Chinese Future Industry Investment Fund Chongqing PSK-Health Sci-tech Development Cincinnati Children's Hospital Medical Center City of Hope CJ CheilJedang ClearPath Cloaked Therapeutics Co-Diagnostics Cohen Veterans Bioscience Cold Spring Harbor Colibri Heart Valve Collagen Solutions Plc Columbus Venture Partners Concentrics Research Consortium AI Corestone Biosciences Cornerstone Animal Health Corning Covenant Animal Health Partn … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
--> Bios | Atropos Therapeutics top of page Home Team Science & Pipeline News Work with us More Use tab to navigate through the menu items. TEAM BIOS Andrew Koff, PhD Founder and Director Andrew has been at Memorial Sloan Kettering Cancer Center for over 25 years, where he started the Laboratory of Cell Cycle Regulation and holds the title of full Member (equivalent to tenured full professor). Andrew is internationally recognized for his work describing the mechanism by which cells make the decision to proliferate or withdraw from the cell cycle into a non-proliferative stat … rschl Scholar. Andrew was also a past recipient of the Boyer Young Investigator Award and the Frederick R. Adler Chair at his academic institution. Andrew has been named as one of the top 250 highly cited researchers in Molecular Biology and Genetics by the Institute for Scientific Information. Andy William D. Tap, MD Co-founder and Director William D. Tap, MD is the Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York. … resistance. He is also focused on understanding cellular gerocoversion and its application to clinical medicine. Bill received his Medical Degree from Jefferson Medical College in Philadelphia and performed his residency in Internal Medicine at the Vanderbilt University Medical Center in Nashville, and his fellowship in Hematology and Medical Oncology at the UCLA Medical Center in Los Angeles. Bill Pauline Pauline Jen Ryan CEO and Director Pauline Jen Ryan is a CEO … s a member of the Board of Directors of Distinguished Young Women, the national scholarship program previously known as America’s Junior Miss. She is one of the inaugural Ambassadors for the New England Region’s American Cancer Society ResearcHERs campaign to support women-led cancer research. She has previously served as an advisor for the Delta V accelerator program at the Martin Trust Center for Entrepreneurship at MIT, advising startups ReviveMed a
--> News | Atropos Therapeutics top of page Home Team Science & Pipeline News Work with us More Use tab to navigate through the menu items. COMPANY UPDATES July 26, 2021 Atropos is highlighted in Longevity Technology’s Senotherapeutics Report. >> August 13, 2020 We are excited to collaborate with The Estée Lauder Companies in a joint development agreement to discover senomodulators! >> November 16, 2020 Atropos is one of the companies selected for Nature Biotechnology’s new article on senolytics. Read more >> June 11, 2020 Initial roun